Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Summary by Denton News Editorial Desk · Byline on the source page: By Decoy Therapeutics, Inc, as published by Denton Record-Chronicle · June 27, 2026 · 1 min read

Photo: Denton Record-Chronicle · view original

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today ann...

Sources and story details

Frequently asked about this story

What is this story about?

When was this published?

This article was first published on June 27, 2026 by Denton Record-Chronicle and curated for Denton News readers.

Who reported this story?

This story was reported by By Decoy Therapeutics, Inc at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards.

Where can I find related coverage?

See more business coverage from Denton News, or browse our daily briefing and topic hubs.

Summary created by	Denton News Editorial Desk — automated, rule-governed
Byline on source page	By Decoy Therapeutics, Inc, as published by Denton Record-Chronicle
Original story	Read at the source
Source published	Jun 27, 2026
AI assistance	Automated summary drawn from the source’s own published text
Prepublication human review	No — editorial rules, flagged-item review, and published samples

More from Denton News